IRUS Total

Specificity of translocator protein-targeted positron emission tomography in inflammatory joint disease

File Description SizeFormat 
s13550-020-00736-9.pdfPublished version1.52 MBAdobe PDFView/Open
Title: Specificity of translocator protein-targeted positron emission tomography in inflammatory joint disease
Authors: Helo, Y
Searle, GE
Borgheese, F
Abraham, S
Azeem, S
Item Type: Journal Article
Abstract: Objective Expression of the translocator protein (TSPO) on inflammatory cells has facilitated imaging of synovitis with TSPO-targeted positron emission tomography (PET). We aimed to quantitatively assess the specificity of the second-generation TSPO PET radioligand, [11C]PBR28, and to generate simplified PET protocols in patients with inflammatory joint disease (IJD) in this pilot study. Methods Three IJD patients (two rheumatoid arthritis and one osteoarthritis) with knee involvement underwent dynamic [11C]PBR28-PET scans before and after administration of 90 mg of oral emapunil (XBD-173), a TSPO ligand the same day. Radial arterial blood sampling was performed throughout the scan, and total radioactivity and radioactive metabolites were obtained. A semi-automated method was used to generate regions of interest. Standardized uptake value (SUV) and SUV ratio corrected for activity in bone and blood between 50 and 70 min (SUVr50–70 bone, SUVr50–70 blood, respectively) and PET volume of distribution (VT) of the radioligand were calculated. Results A mean [11C]PBR28 radioactivity of 378 (range 362–389) MBq was administered. A significant decrease (p < 0.05) in VT, SUVr50–70 bone and SUVr50–70 blood observed after oral emapunil confirmed the TSPO specificity of [11C]PBR28. A decrease in SUV was not observed in the post-block scan. Conclusion [11C]PBR28 is TSPO-specific radioligand in IJD patients. Simplified PET protocols with static PET acquisition can be used in the management and evaluation of novel therapeutics that target TSPO overexpressing cells.
Issue Date: 7-Dec-2020
Date of Acceptance: 17-Nov-2020
URI: http://hdl.handle.net/10044/1/85776
DOI: 10.1186/s13550-020-00736-9
ISSN: 2191-219X
Publisher: Springer
Journal / Book Title: EJNMMI Research
Volume: 10
Copyright Statement: © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Keywords: Science & Technology
Life Sciences & Biomedicine
Radiology, Nuclear Medicine & Medical Imaging
1101 Medical Biochemistry and Metabolomics
1103 Clinical Sciences
1112 Oncology and Carcinogenesis
Publication Status: Published
Article Number: ARTN 147
Appears in Collections:National Heart and Lung Institute

This item is licensed under a Creative Commons License Creative Commons